2 recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
| Phase 2 | 1 | Recruiting 1 |
Follow Douglas Tremblay: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Imetelstat Combinations in Relapsed AML Imetelstat, Azacitidine, Venetoclax - Relapsed Acute Myeloid Leukemia | Phase 1 | Recruiting | Douglas Tremblay | 36 | 2026-01-02 | 2026-04-22 |
| Pacritinib in CMML Pacritinib, Azacitidine - Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Douglas Tremblay | 26 | 2024-09-18 | 2026-08-11 |
Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1)
Azacitidine (2) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (1) · GRN163L peptide (1) · imetelstat (1) · venetoclax (1)
United States (2)